Bioequivalence study of two formulations of rivaroxaban in healthy adult subjects under fasting conditions
American Journal of Pharmacotherapy and Pharmaceutical Sciences · 2023
DOI: 10.25259/ajpps_2023_008 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Pharmacotherapy and Pharmaceutical Sciences, 2023. Verfasst von Evelyn Pena und 2 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Objectives
Oral anticoagulants exert their antithrombotic effect by disrupting the coagulation cascade. Rivaroxaban is the first oral agent to be developed that inhibits the coagulation process by binding directly to Factor Xa in a competitive manner. The aim of this study was to demonstrate the bioequivalence (BE) and safety of a generic formulation of rivaroxaban by comparing their pharmacokinetic (PK) parameters through statistical data and criteria of validation. Oral tablet formulations of 20 mg of a commercial product rivaroxaban reference (R) were tested against a generic product test (T) in 24 healthy adults under fasting condition. Materials and Methods: The study was an open label, balanced, randomized, two-treatment, two-period, two-sequence, single oral dose, and crossover study. Blood samples were collected pre-dose and at specified intervals up to 48-h post-dose to evaluate PK parameters by quantifying the concentration of rivaroxaban in plasma using a validated Liquid chromatography-mass spectrometry (LC-MS/MS) method of analysis. Statistics and confidence intervals (CIs) were calculated for BE purposes.
Results
The geometric means of the T/R ratios and 90% confidence intervals (CIs) were: C max 87.80% (82.74 –93.12%), AUC 0-t 85.96% (81.88–90.24%), and AUC 0-∞ 86.13% (82.2–90.35%). All PK parameters are within BE acceptance range of 80–125% for demonstration of average bioequivalence.
Conclusions
The study demonstrates the BE and well tolerance of both formulations of rivaroxaban in healthy subjects under fasting conditions.
Zitieren
APA
Pena, E., Inatti, A., & Martín, X. S. (2023). Bioequivalence study of two formulations of rivaroxaban in healthy adult subjects under fasting conditions. American Journal of Pharmacotherapy and Pharmaceutical Sciences. https://doi.org/10.25259/ajpps_2023_008
Vancouver
Pena E, Inatti A, Martín XS. Bioequivalence study of two formulations of rivaroxaban in healthy adult subjects under fasting conditions. American Journal of Pharmacotherapy and Pharmaceutical Sciences. 2023. doi:10.25259/ajpps_2023_008
BibTeX
@article{Pena2023,
author = {Pena, Evelyn and Inatti, Alfredo and Martín, Xenón S.},
title = {Bioequivalence study of two formulations of rivaroxaban in healthy adult subjects under fasting conditions},
journal = {American Journal of Pharmacotherapy and Pharmaceutical Sciences},
year = {2023},
doi = {10.25259/ajpps_2023_008}
}
EUVIMED